← Back to Home

Roche’s Anti-CD20 Antibody Recommended for Approval by the European Commission for Systemic Lupus Erythematosus

A phase III trial showed that adding obinutuzumab to standard therapy improved the disease response rate after one year. The European regulatory review has passed an important milestone, with formal approval still awaiting a decision by the European Commission.

By SURL BioNews

For patients with systemic lupus erythematosus whose disease remains active despite standard therapy, recurrent flares often mean a longer treatment course and a risk of organ damage. Roche’s antibody drug obinutuzumab (brand names Gazyva/Gazyvaro) has now moved a step closer to an additional indication in Europe, offering these patients another potential option for disease control.

Roche announced on November 13 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had recommended approval of the drug as an add-on to standard therapy for adults with autoantibody-positive disease that remains moderately to severely active. RTTNews also confirmed in a report that day that the recommendation was based on the phase III ALLEGORY trial; formal marketing authorization still requires a decision by the European Commission.

ALLEGORY was a randomized, double-blind, placebo-controlled trial involving 303 adult patients, with both groups continuing to receive standard therapy. At week 52, 76.7% of patients in the group receiving additional obinutuzumab met the SRI-4 response criteria, compared with 53.5% in the placebo group. The adjusted difference between the groups was 23.1 percentage points, with a 95% confidence interval of 12.5 to 33.6 percentage points, and was statistically significant.

SRI-4 is a composite measure of response to lupus treatment used to determine whether disease activity has improved to a specified degree. This result supports an additional benefit from the drug on top of existing treatment, but meeting the response criteria does not mean the disease has been cured, nor can it be directly interpreted as evidence that future organ damage has been prevented. The trial’s comparator design also cannot establish whether it is superior to other marketed biologic therapies for lupus.

Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody that works by targeting B cells. B cells are involved in the autoimmune response in lupus, so depleting these cells is one therapeutic approach to reducing disease activity. The significance of this review lies in advancing this strategy for patients with systemic disease that remains inadequately controlled after standard therapy, although the actual eligibility criteria will depend on the final approval.

Alongside efficacy, safety also needs to be weighed. A publicly available conference abstract from ALLEGORY reported serious adverse events in 15.9% of the obinutuzumab group and 11.9% of the placebo group. This numerical difference alone is insufficient to establish causality, but it reminds readers that the benefits of disease control must be assessed alongside the burden of treatment. This positive review opinion brings a new option closer to clinical use, while longer-term benefits and risks still require further follow-up.

References

  1. Roche
  2. RTTNews